Affiliation: ALTANA Pharma AG
- Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitorsL Wollin
ALTANA Pharma, Byk Gulden Strasse 2, 78467 Konstanz, Germany
Pulm Pharmacol Ther 19:343-52. 2006..This study suggests that roflumilast has anti-inflammatory action and provides rationale for the investigation of roflumilast in asthmatic patients...
- Roflumilast inhibition of pulmonary leukotriene production and bronchoconstriction in ovalbumin-sensitized and -challenged Guinea pigsLutz Wollin
ALTANA Pharma, Konstanz, Germany
J Asthma 42:873-8. 2005..06 mg/kg) and LTB4 (ID50 = 0.05 mg/kg) release versus placebo-treated animals. Roflumilast did not affect LTD4-induced bronchoconstriction. These findings support the role of roflumilast as an anti-inflammatory treatment for asthma...
- Cyclooxygenase-inhibition enhances the effects of rSP-C surfactant therapy in a rat lavage model of acute respiratory distress syndrome (ARDS)Dietrich Häfner
Department of Respiratory Pharmacology, Byk Gulden, Konstanz, Germany
Exp Toxicol Pathol 55:59-68. 2003....
- Inhibition of inflammation and remodeling by roflumilast and dexamethasone in murine chronic asthmaRakesh K Kumar
Department of Pathology, University of New South Wales, Sydney, Australia
J Pharmacol Exp Ther 307:349-55. 2003..Roflumilast did not diminish accumulation of transforming growth factor-beta1, suggesting that it might affect remodeling by mechanisms distinct from glucocorticoids...
- Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smokePiero A Martorana
Department of Physiopathology and Experimental Medicine, University of Siena, Via Aldo Moro 6, I 53100 Siena, Italy
Am J Respir Crit Care Med 172:848-53. 2005..There is a need for new agents capable of suppressing the inflammatory response in chronic obstructive pulmonary disease...